drugset / Trial / NCT00880464
Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer. The vaccine is made by genetically modifying a patient's own tumor cells to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate the immune response
Timeline
- Start
- 2006-01-01
- Primary completion
- 2011-10
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous, Lethally Irradiated Breast Cancer Cells | Vaccine | 100000 cells | Subcutaneous |
| Subject | Autologous, Lethally Irradiated Breast Cancer Cells | Vaccine | 1e+06 cells | Subcutaneous |
| Subject | Autologous, Lethally Irradiated Breast Cancer Cells | Vaccine | 4e+06 cells | Subcutaneous |
| Subject | Autologous, Lethally Irradiated Breast Cancer Cells | Vaccine | 1e+07 cells | Subcutaneous |